- Genome editing, a new set of methods of genetic engineering, enables targeted interventions in somatic as well as in germline cells in humans.
- Genome editing can help improve somatic gene therapies and expand their scope of application. Initial approaches are currently being tested in clinical trials.
- Research and innovation policy impulses are needed for the development of gene- and cell-based therapies, particularly for rare diseases. The costs of the procedureslikely will remain high. Accordingly, novel reimbursement models are needed.
- Unresolved health risks and fundamental ethical issues preclude a clinical application of germline interventions.